CD274 and neoplasm: As NSCLC patients with high PD‐L1 tumor expression benefit from anti‐PD‐L1/PD‐1 blockade therapies (Borghaei et al, 2015), we assessed PD‐L1 tumor expression and its association to responses in G1 and G2 patient cohorts for whom PD‐L1 tumor expression could be determined.